MicroCapClub Invitational: Misonix (MSON)

Ian Cassel 2013 Invitational, Blog 3 Comments

The U.S. medical device industry continues to grow at a brisk pace, thanks to an aging Baby Boomer population, high unmet medical needs and increased incidence of lifestyle diseases (including cardiovascular diseases, diabetes, hypertension and obesity). The global medical device market is expected to reach $300 billion by 2017 with a CAGR of 6.1% over the next several years (2011-2017).  Misonix (MSON) is aggressively pursuing a $3 billion+ piece of the market with their ultrasonic medical devices. Last quarter the company grew revenues 42%, with the highest growth occurring internationally. Misonix’s three core products grew at an impressive 220% (BoneScalpel), 97% (SonicOne), and 21% (SonaStar) year over year respectively. More importantly we expect profitable growth in 2013 and beyond. Listen to CEO Michael McManus as he tells the story.

Disclosure:  No position. This presentation was recorded on January 30th. All participants were not active in the stock on January 30th. The company DID NOT compensate MicroCapClub to present.

MicroCapClub Invitational Presentation Lineup and Dates:

January 3rd: Where Food Comes From (WFCF)   [VIEW PRESENTATION]
January 7th: OptimizeRx (OPRX)   [VIEW PRESENTATION]
January 10th: Abtech Holdings (ABHD)   [VIEW PRESENTATION]
January 14th: Parametric Sound (PAMT)   [VIEW PRESENTATION]
January 17th: NXT Energy (SFD.V)   [VIEW PRESENTATION]
January 21st: Noble Roman’s (NROM)   [VIEW PRESENTATION]

January 31st: Greystone Logistics (GLGI)

February 4th: Charles & Colvard (CTHR)

February 7th: rVue Holdings (RVUE)

February 11th: BioSyent (RX.V)

February 13th: Vertex Energy (VTNR)

The MicroCapClub (mc2) is an exclusive microcap forum focused on microcap companies (sub $300m market cap). The MicroCapClub was created and founded by Ian Cassel as a way to share ideas and to learn from other seasoned like-minded microcap investors. Our goal at MicroCapClub.com is quality membership and quality stock ideas.  If you are an experienced microcap investor, feel free to Apply today.

Comments 3

  1. —any comments on yesterdays dismal quarterly report? My thoughts, when you change the sales model from a distributor to a direct sales approach, you encounter considerable upfront expenses that often take several quarters before they bear fruit.

    1. yes, mixed bag, but l/t potential grwoth of bonescalpel is very much intact, given excellent feature/benefit profile. Hard to model and going to be lumpy quarter to quarter though.

      1. —what is the long term potential for Bone Scalpel? Also, what is the long term potential for SonicOne? Has management projected any numbers for those products?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.